274 related articles for article (PubMed ID: 29712574)
1. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
2. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma.
Donovan LK; Delaidelli A; Joseph SK; Bielamowicz K; Fousek K; Holgado BL; Manno A; Srikanthan D; Gad AZ; Van Ommeren R; Przelicki D; Richman C; Ramaswamy V; Daniels C; Pallota JG; Douglas T; Joynt ACM; Haapasalo J; Nor C; Vladoiu MC; Kuzan-Fischer CM; Garzia L; Mack SC; Varadharajan S; Baker ML; Hendrikse L; Ly M; Kharas K; Balin P; Wu X; Qin L; Huang N; Stucklin AG; Morrissy AS; Cavalli FMG; Luu B; Suarez R; De Antonellis P; Michealraj A; Rastan A; Hegde M; Komosa M; Sirbu O; Kumar SA; Abdullaev Z; Faria CC; Yip S; Hukin J; Tabori U; Hawkins C; Aldape K; Daugaard M; Maris JM; Sorensen PH; Ahmed N; Taylor MD
Nat Med; 2020 May; 26(5):720-731. PubMed ID: 32341580
[TBL] [Abstract][Full Text] [Related]
3. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
4. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
5. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
6. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
7. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
[TBL] [Abstract][Full Text] [Related]
8. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S
Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166
[TBL] [Abstract][Full Text] [Related]
9. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
11. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
[TBL] [Abstract][Full Text] [Related]
12. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
13. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
14. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.
Xu J; Meng Q; Sun H; Zhang X; Yun J; Li B; Wu S; Li X; Yang H; Zhu H; Aschner M; Relucenti M; Familiari G; Chen R
Cell Death Dis; 2021 Nov; 12(12):1109. PubMed ID: 34839348
[TBL] [Abstract][Full Text] [Related]
15. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19
Webster B; Xiong Y; Hu P; Wu D; Alabanza L; Orentas RJ; Dropulic B; Schneider D
Mol Ther; 2021 Sep; 29(9):2691-2706. PubMed ID: 33974997
[TBL] [Abstract][Full Text] [Related]
16. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
17. Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
Kouro T; Higashijima N; Horaguchi S; Mano Y; Kasajima R; Xiang H; Fujimoto Y; Kishi H; Hamana H; Hoshino D; Himuro H; Matsuura R; Tsuji S; Imai K; Sasada T
Int J Cancer; 2024 May; 154(10):1828-1841. PubMed ID: 38212893
[TBL] [Abstract][Full Text] [Related]
18. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208
[TBL] [Abstract][Full Text] [Related]
19. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
